Langston & Lott, PLLC
Zantac Lawsuit

On April 1, 2020, the Food and Drug Administration (FDA’s) pulled the heartburn medicine Zantac and generic drugs containing its ingredient ranitidine off the market due to the presence of the probable human carcinogen NDMA.

Last year, an independent pharmacy alerted the FDA of testing that revealed NDMA in some ranitidine products. At that time, the FDA said that it did not have enough scientific evidence to recommend that consumers stop using it. Prompted by information gathered by third-party laboratories, the FDA conducted new testing and evaluation that revealed more cause for concern. The new data confirmed that NDMA levels increase in ranitidine even under normal storage conditions, and increase significantly in samples stored at higher temperatures, including temperatures the product may have been exposed to during distribution and handling by consumers. The older the ranitidine was, or the longer the length of time since it was manufactured, the greater the level of NDMA. “These conditions may raise the level of NDMA in the ranitidine product above the acceptable daily intake limit,” the FDA said. Previous studies have found that it is also possible that medicines containing ranitidine can cause NDMA to form in the body after ingestion.

The makers of Zantac have been aware that NDMA was a possible human carcinogen for years. Attorneys Casey Lott and Thomas Cooley are actively investigating potential claims involving regular Zantac/ ranitidine use that may have led to cancer and are accepting cases from individuals who took Zantac at least once a week for six months and were diagnosed with one of the following cancers:​